CORDIS
EU research results

CORDIS

English EN

Market introduction of a revolutionary innovative cardiac stimulation system for the prevention and termination of post-operative atrial fibrillation

Project information

Grant agreement ID: 946899

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 2 814 215

  • EU contribution

    € 1 969 950,50

Coordinated by:

OSYPKA AG

Germany

Objective

The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a
significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently
occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and
duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons
results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable
ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our
new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative
atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing
as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers
are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing &
cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar
to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF •
Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings
for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication
required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for
OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second
time in our history

Coordinator

OSYPKA AG

Address

Earl H Wood Strasse 1
79618 Rheinfelden Baden

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 969 950,50

Project information

Grant agreement ID: 946899

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 2 814 215

  • EU contribution

    € 1 969 950,50

Coordinated by:

OSYPKA AG

Germany